28-7 Therapeutics raises $65M for cancer drugs aimed at tumor-suppressing RNA

3D medical background with DNA strand
28-7’s lead program hopes to foster the tumor suppressor microRNA Let-7, which regulates the translation of oncogenes, by inhibiting the protein Lin28. (kirstypargeter/iStock/Getty Images Plus)

Twentyeight-Seven Therapeutics has launched with $65 million in venture capital to fund its treatments for a variety of cancers, which aim to modulate noncoding strands of microRNA to increase the levels of tumor-suppressing genes.

The Cambridge, Massachusetts-based startup’s founding investor, MPM Capital, co-led the series A round with the Novartis Venture Fund. Johnson & Johnson Innovation, Vertex Ventures HC, Longwood Fund and Astellas Venture Management also participated in the financing.

In addition, 28-7 brought on Shomir Ghosh, Ph.D., to be its chief scientific officer. Ghosh most recently served as CSO and founding scientist at IFM Therapeutics. Before that, he helped direct drug discovery at GlaxoSmithKline and later served as VP of drug discovery at GSK’s short-lived immunology spinout, Tempero Pharmaceuticals.

FierceBiotech Executive Breakfast

Getting Real: The Changing Tide on Real-World Evidence in Drug Development

Join FierceBiotech and a panel of industry experts for an executive breakfast at BIO. We will discuss the impacts of real-world evidence on drug development and address the important questions that companies are facing including where to find the right talent & technology and how to deploy it internally or with partners. Join us in Philadelphia on June 5th for this important discussion.

Founded in 2016, the company’s core technology comes from four Harvard Medical School professors in biological chemistry, molecular pharmacology and RNA medicine: Richard Gregory, Ph.D.; Frank Slack, Ph.D.; Piotr Sliz, Ph.D.; and George Daley, M.D., Ph.D., dean of the faculty of medicine—who have collaborated for years on the role of noncoding RNAs in disease and identifying related protein targets.

28-7’s lead small-molecule program hopes to increase the levels of the tumor suppressor microRNA Let-7, which regulates the translation of oncogenes within cells. Low levels of Let-7 have been correlated with stronger cancer aggressiveness.

The company doesn’t plan to directly target the RNA itself, but instead focus on RNA-modulating proteins to allow broader drug access to cells and tissues. Its main protein target is the inhibition of Lin28, which reduces levels of Let-7 and has been shown to promote cellular transformation and tumorigenesis.

“Our founders have made important scientific contributions to the field of ncRNA biology, including the discovery of the Lin28/Let-7 pathway and its role in normal development, metabolism, and malignancy,” said co-founder Daley, who serves as chairman of the company’s scientific advisory board. “Overall, our studies have established Lin28/Let-7 as a major regulatory pathway in stem cells and cancer.”

“We felt that the time was right to move these insights from the laboratory to pharmaceutical development, and we are very pleased by the progress the company achieved in the first two years of its existence,” he said.

Suggested Articles

Yale researchers discovered that AstraZeneca’s anti-VEGF cancer drug cediranib may boost the effectiveness of PARP inhibitors.

The FBI has launched its own probe into some of the world’s largest medtech companies, stemming from a Brazilian corruption case, Reuters reports.

AbbVie became yet another biopharma learning that aggressive brain cancer glioblastoma is one of the toughest cancers out there.